From the dawn of Crispr in 2012, medical scientists have recognized the gene-editing tool’s potential to treat, or even cure, genetic diseases.
New data from Intellia Therapeutics is making their hopes more realistic than ever. The company’s Crispr therapy was able to significantly lower patients’ levels of a misfolded liver protein and keep them low for months.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
We humbly apologize for the inconvenience.